APA (7th ed.) Citation

JJ, E., PP, C., ML, M., H, H., M, C., GE, C., . . . E, D. (2025). Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab. The Journal of infectious diseases, 231(6), 1440. https://doi.org/10.1093/infdis/jiaf159

Chicago Style (17th ed.) Citation

JJ, Eron, et al. "Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab." The Journal of Infectious Diseases 231, no. 6 (2025): 1440. https://doi.org/10.1093/infdis/jiaf159.

MLA (9th ed.) Citation

JJ, Eron, et al. "Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab." The Journal of Infectious Diseases, vol. 231, no. 6, 2025, p. 1440, https://doi.org/10.1093/infdis/jiaf159.